Lupus & antiphospholipid syndrome
Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre–multidisciplinary retrospective study
Authors' conclusion
ANI showed rapid, multisystem efficacy in refractory DM with significant steroid-sparing effects and a favourable safety profile.
Study context
- Population
- Patients with refractory systemic DM
- Participants
- 30 patients
- Outcome
- Cutaneous activity (CDASI-A), median, baseline to month 1
- Follow-up
- Month 1
Methodological detailsmulticentre, multidisciplinary, compassionate use
- Multicentre
- Multidisciplinary
- Compassionate use
Main finding
As reported in the abstract
- CDASI-A baseline
- 23 [IQR 10.8-30.5]
- CDASI-A month 1
- 6 [IQR 3-10]
- Change baseline to month 1
- P < 0.001
Observational data: associations, not effects.
Safety
Adverse events (mild)
- Patients with AEs, all mild
- 16.7%
- Death from pneumonia (89-year-old patient)
- 1
Treatment discontinuation
- Discontinued anifrolumab (ANI) for efficacy loss
- 1
- Required upadacitinib for refractory pruritus
- 1
Original publication
Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre–multidisciplinary retrospective study. Rheumatology (Oxford). Published 16 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →